Insulet Corporation
Insulet Corporation (Nasdaq: PODD) develops, manufactures, and sells continuous insulin delivery systems for people with insulin-dependent diabetes. Its Omnipod platform includes Omnipod 5, an automated insulin delivery system that uses glucose-monitor data to adjust insulin delivery; Omnipod DASH, a tubeless insulin… From the company’s description.
In fiscal 2025, Insulet Corporation reported revenue of $2.71B, up 30.7% from fiscal 2024, and net income of $247.10M. Its operating margin was 17.5%, and operations generated $569.30M in cash. Over the twelve months to Jun 30, 2026, revenue was $3.05B.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Insulet Corporation does
In the company’s own words
Insulet Corporation (Nasdaq: PODD) develops, manufactures, and sells continuous insulin delivery systems for people with insulin-dependent diabetes. Its Omnipod platform includes Omnipod 5, an automated insulin delivery system that uses glucose-monitor data to adjust insulin delivery; Omnipod DASH, a tubeless insulin management system; and the legacy Classic Omnipod system, which is being phased out. The wearable, disposable Pods deliver insulin without the external tubing used by conventional pumps, and Omnipod 5 can be controlled with a handheld device or compatible smartphone app. Insulet also makes Pods for Amgen’s Neulasta Onpro kit, which delivers a drug used to help reduce infection risk after intense chemotherapy. The company sells through wholesalers, pharmacies, distribution partners, and directly to consumers, serving users, clinicians, and healthcare payors in the United States and international markets. It also offers data-management and analytics tools, including Omnipod Discover. Insulet reported approximately 5,400 full-time employees as of December 31, 2025, and its products were available in 25 countries. Its website is http://www.insulet.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Surgical & Medical Instruments
- Headquarters
- ACTON, MA
- Fiscal year end
- December
- CIK
- 1145197
- SIC
- 3841
Financial performance, year by year
Fiscal 2013–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Insulet Corporation — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Insulet Corporation’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Insulet Corporation’s bonds, as funds hold them
Funds report holding 1 issues of Insulet Corporation’s debt, $171.01M at market value — what funds hold, not the company’s total debt. Weighted-average coupon 6.50%, maturing 2033 to 2033.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Insulet Corporation and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Insulet Corporation's earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Insulet Corporation's last four quarterly filings that the numbers alone won't show?”